Cargando…
Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
OBJECTIVE: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540520/ https://www.ncbi.nlm.nih.gov/pubmed/32583883 http://dx.doi.org/10.1002/ana.25831 |
_version_ | 1783591227680096256 |
---|---|
author | Mulder, Inge A. Li, Mei de Vries, Tessa Qin, Tao Yanagisawa, Takeshi Sugimoto, Kazutaka van den Bogaerdt, Antoon Danser, A. H. Jan Wermer, Marieke J. H. van den Maagdenberg, Arn M. J. M. MaassenVanDenBrink, Antoinette Ferrari, Michel D. Ayata, Cenk |
author_facet | Mulder, Inge A. Li, Mei de Vries, Tessa Qin, Tao Yanagisawa, Takeshi Sugimoto, Kazutaka van den Bogaerdt, Antoon Danser, A. H. Jan Wermer, Marieke J. H. van den Maagdenberg, Arn M. J. M. MaassenVanDenBrink, Antoinette Ferrari, Michel D. Ayata, Cenk |
author_sort | Mulder, Inge A. |
collection | PubMed |
description | OBJECTIVE: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. METHODS: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP‐induced relaxations in mouse and human vessels, in vitro. RESULTS: Olcegepant (1mg/kg, single dose) increased infarct risk after 12‐ to 20‐minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60‐minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60% after 20‐minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60‐minute occlusion. In familial hemiplegic migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30‐minute occlusion (1.6‐fold, p = 0.017). Both gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10‐fold more potent than rimegepant on CGRP‐induced relaxations in mouse aorta. INTERPRETATION: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition. ANN NEUROL 2020;88:771–784 |
format | Online Article Text |
id | pubmed-7540520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75405202020-10-09 Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice Mulder, Inge A. Li, Mei de Vries, Tessa Qin, Tao Yanagisawa, Takeshi Sugimoto, Kazutaka van den Bogaerdt, Antoon Danser, A. H. Jan Wermer, Marieke J. H. van den Maagdenberg, Arn M. J. M. MaassenVanDenBrink, Antoinette Ferrari, Michel D. Ayata, Cenk Ann Neurol Research Articles OBJECTIVE: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. METHODS: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP‐induced relaxations in mouse and human vessels, in vitro. RESULTS: Olcegepant (1mg/kg, single dose) increased infarct risk after 12‐ to 20‐minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60‐minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60% after 20‐minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60‐minute occlusion. In familial hemiplegic migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30‐minute occlusion (1.6‐fold, p = 0.017). Both gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10‐fold more potent than rimegepant on CGRP‐induced relaxations in mouse aorta. INTERPRETATION: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition. ANN NEUROL 2020;88:771–784 John Wiley & Sons, Inc. 2020-08-07 2020-10 /pmc/articles/PMC7540520/ /pubmed/32583883 http://dx.doi.org/10.1002/ana.25831 Text en © 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Mulder, Inge A. Li, Mei de Vries, Tessa Qin, Tao Yanagisawa, Takeshi Sugimoto, Kazutaka van den Bogaerdt, Antoon Danser, A. H. Jan Wermer, Marieke J. H. van den Maagdenberg, Arn M. J. M. MaassenVanDenBrink, Antoinette Ferrari, Michel D. Ayata, Cenk Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice |
title | Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice |
title_full | Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice |
title_fullStr | Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice |
title_full_unstemmed | Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice |
title_short | Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice |
title_sort | anti‐migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540520/ https://www.ncbi.nlm.nih.gov/pubmed/32583883 http://dx.doi.org/10.1002/ana.25831 |
work_keys_str_mv | AT mulderingea antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT limei antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT devriestessa antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT qintao antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT yanagisawatakeshi antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT sugimotokazutaka antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT vandenbogaerdtantoon antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT danserahjan antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT wermermariekejh antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT vandenmaagdenbergarnmjm antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT maassenvandenbrinkantoinette antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT ferrarimicheld antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice AT ayatacenk antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice |